ABSTRACT: A series of imidazo[1,5-a]quinoline derivatives was designed and synthesized as central benzodiazepine receptor (CBR) ligands. Most of the compounds showed high CBR affinity with K i values within the submicromolar and subnanomolar ranges with interesting modulations in their structure−affinity relationships. In particular, fluoroderivative 7w (K i = 0.44 nM) resulted in the most potent ligand among the imidazo[1,5-a]quinoline derivatives described so far. Overall, these observations confirmed the assumption concerning the presence of a large though apparently saturable lipophilic pocket in the CBR binding site region interacting with positions 4 and 5 of the imidazo[1,5-a]quinoline nucleus. The in vivo biological characterization revealed that compounds 7a,c,d,l,m,q,r,w show anxiolytic and antiamnestic activities without the unpleasant myorelaxant side effects of the classical 1,4-BDZ. Furthermore, the effect of 7l,q,r, and 8i in lowering lactate dehydrogenase (LDH) release induced by ischemia-like conditions in rat brain slices suggested neuroprotective properties for these imidazo[1,5-a]quinoline derivatives.
■ INTRODUCTION
The neurotransmitting action of γ-aminobutyric acid (GABA) at the GABA A chloride channel complex modulates the excitability of many central nervous system (CNS) pathways. 1 GABA A receptors are ligand-gated ion channels (LGICs) belonging to the Cys-loop superfamily, the same as nicotinic acetylcholine, glycine, zinc-activated, and 5-HT 3 receptors. Cysloop receptors are characterized by the assembly of five subunits, which form pentameric arrangements around a central ion-conducting pore and are the targets of many drugs. 1 The function of GABA A receptors is regulated, in addition to the agonist binding site, by allosteric sites interacting with a large variety of agents. 2 Positive modulators of the GABA A receptors, such as the classical 1,4-benzodiazepine (BDZ) diazepam (1, Figure 1 ), are therapeutically employed as sedatives, muscle relaxants, anxiolytics, and anticonvulsants, whereas negative GABA A modulators (i.e., BDZ inverse agonists) show anxiogenic and convulsant effects. 3−6 Finally, neutral modulators, such as the imidazo [1,5-a] [1, 4] benzodiazepines flumazenil (2), bind to GABA A receptor but have no intrinsic activity at the central benzodiazepine receptor (CBR). Thus, flumazenil is recognized to antagonize the activity of both positive and negative GABA A modulators acting via the CBR.
Because positive modulators show amnesic effects in animal and man, 7−10 negative modulators were assumed to possess procognitive properties. 11, 12 However, the use of nonselective CBR inverse agonists in the treatment of neurological disorders associated with cognitive impairment was limited by their anxiogenic and convulsant effects.
A large number of subunits (i.e., α 1−6 , β 1−4 , γ 1−4 , δ, ε, π, θ, and ρ 1−3 ) has been cloned and sequenced, but most of GABA A receptors are composed of α, β, and γ-subunits arranged in a 2:2:1 stoichiometry. 14 In fact, among the multitude of theoretically possible combinations deriving from the coassembly of the subunits, only the receptor subtypes containing a γ 2 or γ 3 15 subunit in conjunction with α 1 , α 2 , α 3 , or α 5 appear to bind BDZ ligands with significant affinity. The CBR binding domain is assumed to be located at the interface between α and γ subunits, which contribute to the building of the active site with their amino acid residues. 16 Investigations based on molecular genetic or pharmacological approaches suggested that α 1 subunit is involved in the sedative and muscle relaxant effects of the nonselective BDZ agonists, whereas α 2 or α 3 can be responsible for the anxiolytic and anticonvulsant effects. 17−19 The recognition of the pharmacological and physiological roles of α subunits in GABA A receptor subtype functions has stimulated new interest in this receptor system as the target for the development of drugs showing fewer side effects with respect to the classical benzodiazepines (e.g., nonsedating anxiolytics) or possessing different indications with respect to the classical benzodiazepines (e.g., analgesics, cognitionenhancing drugs). 20−27 A number of compounds has been developed that show GABA A receptor subtype selectivity. 20 In particular, subtype-selective GABA A receptor ligands were obtained either by selective binding (i.e., by forming a receptor−ligand complex with a particular receptor subtype) or by selective efficacy (i.e., by eliciting a biological response after binding to the receptor). These two properties are both important in defining the potency profile. 20 Very interestingly, the full range of intrinsic efficacies observed in the series of imidazo [1,5-a] [1, 4] benzodiazepine derivatives 3 was modulated in a rather subtle manner by the substitution pattern. 28, 29 A similar behavior was observed when the seven-membered ring of the benzodiazepine system was contracted as in the series of imidazo [1,5-a] quinoxaline derivatives 4, which were developed in the 1990s in Upjohn laboratories. 30−35 The large body of work performed by the Upjohn researchers led to the proposal of the existence of a second low affinity-binding site on GABA A receptors, the occupancy of which (at high drug concentrations) may reverse the positive allosteric action on CBR and potentially minimize dependence and abuse liability. 36 Among the large number of imidazo [1,5-a] quinoxaline derivatives developed, compound 4a (see Figure 1 ) was shown to induce a negative allosteric modulation via this second low affinity binding site. 36 On the basis of the huge amount of structure−activity relationship (SAR) data on imidazo [1,5-a] quinoxaline derivatives 4, the structure of 4a was easily translated into the imidazo [1,5-a] quinoline one of 5 (see Figure 1 ), which was considered as a drug candidate for the treatment of anxiety, but its development was discontinued for safety reason (i.e., centrally mediated respiratory depression having lethal effects). 37 The identification of 5 as a candidate for development studies was apparently performed among a limited set of imidazo [1,5-a] quinoline derivatives so that the available SAR data on this class of CBR ligands is limited. In general, the analysis of the available SAR data suggested that bulky substituents are tolerated by CBR binding site when they are located in the ligand region corresponding to positions 4 and 5 of the imidazo [1,5-a] quinoline nucleus consistently with the results obtained with 5-HT 3 receptor ligands based on quinoline structure 6. 38, 39 Similarly, these bulky substituents appeared to play a role in modulating the intrinsic efficacy. 39 These observations, together with the structural analogies existing between GABA A and 5-HT 3 receptors, led us to apply the approach used in studying 5-HT 3 receptors to the characterization of CBR binding features by means of the design, synthesis, and pharmacological characterization of imidazo [1,5-a] 
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Article suitable 2-chloroquinoline derivatives 11−24 with ethyl isocyanoacetate or tert-butyl isocyanoacetate in the presence of potassium tert-butoxide providing 7a−i,k−m,o−y (Scheme 1) in the yields reported in Table 1 . The structure of 7p,s,t was confirmed by crystallographic studies (see Supporting Information).
The starting 2-chloroquinoline derivatives were either compounds known (see Table 1 ) or prepared by standard methodology. 38, 40 On the other hand, target propargylamide derivative 7n was synthesized from tert-butyl ester 7k via acid 7j (Scheme 2).
Acyl chloride 25 38 was reacted with potassium tert-butoxide in dry THF to obtain ester 16, which was used in the abovedescribed imidazo-annulation with ethyl isocyanoacetate, affording diester 7k. The cleavage of the tert-butyl ester moiety of the latter with formic acid gave the expected carboxylic acid 7j, which was in turn transformed via acyl chloride into the expected propargylamide 7n.
The target imidazo [1,5-a] quinoline derivatives bearing substituents in position 7 of the tricyclic nucleus was carried out as outlined in Scheme 3.
The appropriately substituted quinolinone derivatives 26a,b 41 were converted into the corresponding 2-chloroquinoline derivatives 27a,b by reaction with phosphorus oxychloride. The amidation of the carboxyl group of 27a,b afforded the expected amides 22−24, which were used in the abovedescribed imidazo-annulation with ethyl isocyanoacetate or tertbutyl isocyanoacetate to obtain target compounds 7w,x,y. Bromoderivative 7y was then used in Sonogashira coupling 3 , tertBuOK, DMF. Substituents: see Table 1 . 
Article reaction with trimethylsilylacetylene to afford 7aa, which was promptly desilylated with into 7z.
Most of the target imidazo[1,5-a]quinoline derivatives bearing the phenyl substituents in position 5 of the tricyclic nucleus was accomplished as sketched in Scheme 4, while the preparation of compound 8i is described in Scheme 5.
Imidazo-annulation of suitable 2-chloro-4-phenylquinoline derivatives 28−31 42 with ethyl isocyanoacetate or tert-butyl isocyanoacetate in the presence of potassium tert-butoxide gave target derivatives 8a,b,e,g,h. The cleavage of the tert-butyl ester moiety of esters 8b,e with formic acid gave carboxylic acid derivatives 32 and 33, which were converted via 2,3,5,6-tetrafluorophenyl esters into the desired amides 8c,d,f.
Lithium aluminum hydride reduction of ester 30 gave hydroxymethylquinoline derivative 34, which was first protected by reaction with tert-butyldimethylsilyl chloride (TBDMSCl) and then submitted to the conditions of the imidazo-annulation with ethyl isocyanoacetate or tert-butyl isocyanoacetate to afford imidazo[1,5-a]quinoline 36, which was promptly desilylated into target 8i.
Finally, the imidazo-annulation was applied also to chloroderivative 37 43 to obtain tetracyclic target compound 9 and to quinoxalinone derivatives 38 and 39.
31 However, these latter intermediates required a more complex reaction pathway consisting of a first activation step with diethyl chlorophosphate followed by a second step of annulation with ethyl isocyanoacetate or tert-butyl isocyanoacetate in the presence of potassium tert-butoxide to obtain reference imidazo[1,5-a]quinoxaline 10a−d (Scheme 6). 31 The structure of 10a−c was confirmed by crystallographic studies (see Supporting Information).
In Vitro Binding. The affinity of the imidazo[1,5-a]quinoline derivatives 7a−aa, 8a−g, 9, and 10a−c for CBR in bovine cortical membranes was measured by means of competition experiments against the radiolabeled antagonist Tables 2 and 3 . The in vitro efficacy of the target compounds was tentatively estimated by measuring the GABA ratio (GR, expressed as a ratio of K i without GABA/K i with GABA), which is considered reasonably predictive of the pharmacological profile of a CBR ligand. 44 
Article Most of the compounds were found to inhibit the specific binding of radiolabeled flumazenil at the bovine CBR with K i values within the submicromolar and the subnanomolar ranges with the full range of the intrinsic efficacy as predicted by GABA ratio values (0.52−1.6).
The analysis of the structure−activity relationships confirmed the importance of the substituents in positions 4 and 5 of the imidazo [1,5-a] quinoline scaffold in modulating both the CBR affinity and the intrinsic efficacy ( Figure 3) . The most potent CBR ligands were obtained in the series of imidazo [1,5-a] quinoline derivatives bearing a N,N-dipropylaminocarbonyl group at position 5 of the tricyclic nucleus. However, also other lipophilic substituents are tolerated in the binding site region interacting with position 5 of the imidazo [1,5-a] quinolone, namely N,N-dimethylaminocarbonyl, N-methybutylaminocarbonyl, N-methypropargylaminocarbonyl, N-methybenzylaminocarbonyl, tert-butoxycarbonyl, and phenyl groups (Figure 3) .
However, the tolerance to large substituents in position 5 appeared to be conditioned by the presence of additional steric bulk in position 4 of the tricyclic scaffold ( Figure 4 ). c The values were obtained in rat cortical membranes.

Article
In fact, in the dipropylamido subseries (Figure 4 ), the increase of the alkyl side chain length led to a stepwise decrease in CBR affinity with a rapid acceleration in propyl derivatives 7u,v. This result can be rationalized in terms of interactions between the ester group and the alkyl moiety in position 4 but also with by assuming that the lipophilic pocket can be saturated as previously observed in 5-HT 3 receptors. 38 On the other hand, in the imidazo [1,5-a] quinoline subseries bearing a phenyl group in position 5 (Figure 4) , the effects of the substituents in position 4 were highly variable and appeared to depend on the stereoelectronic features of the substituent itself.
In general, small substituents such as H, CH 3 , and CH 2 OH are tolerated better than the bulkier carbethoxy group of compound 8g, but the spacing of the ester group by a methylene bridge as in 8h restored nanomolar CBR affinity, suggesting the involvement of specific interactions. 
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Article As already observed in related CBR ligands, the presence of small atoms such as H or F in position 7 is required for nanomolar CBR affinity, whereas the presence of the bulkier bromine atom produces a significant drop in CBR affinity that became dramatic (i.e., almost 2 orders of magnitude) when alkyne substituents are present in this position as in compounds 7z−aa ( Figure 5 ).
It is noteworthy that the beneficial effect of the fluorine substituent was less evident in imidazo [1,5- In Vitro Efficacy in 36 Cl − Uptake Assay in Rat Cerebrocortical Synaptoneurosomes. The comparison of the GABA ratio values showed a rather complex pattern in the structure−activity relationships of imidazo [1,5-a] quinoline derivatives 7a−aa, 8a−g, 9, and 10a−c. In general, the agonist-like properties appeared to be linked to the presence of relatively small substituents (i.e., 7a,b), whereas the presence of large lipophilic substituents appeared to be associated with antagonist-like features. However, ligands showing apparently different intrinsic efficacy were present in the same subseries without evidencing a clear trend. This could be due both to the complexity of the interaction and to possible experimental errors.
Thus, the predictive capability of GABA ratio values was evaluated in the limited set of reference imidazo[1,5-a]-quinoxaline derivatives 10b−d by means of a more direct measure of in vitro efficacy consisting in 36 Cl − uptake assay in 
Article rat cerebrocortical synaptoneurosomes. 48, 49 The synaptic chloride conductance effected by GABA activating the GABA A receptor complex is modulated by ligands acting at the CBR. In particular, agonists increase the current, antagonists are ineffective, and inverse agonists decrease the ion flow. The results shown in Figure 7 suggested that reference 10b behaved as a CBR antagonist in agreement with its GABA ratio values (0.98−1.04) and with the data described in the literature. 31 Compound 10d (GABA ratio = 1.0) showed a very slight increase of 36 Cl − influx, behaving as a partial agonist characterized by a very low intrinsic efficacy. On the other hand, an even slight decrease in the ion flow was observed with compound 10c (GABA ratio in bovine CBR = 0.75, in human CBR = 0.95), which could be therefore classified either as a partial inverse agonist showing a very low intrinsic efficacy or as an antagonist. No massive 36 Cl − influx was promoted by these reference compounds in agreement with their antagonist-like or partial inverse agonist properties as predicted by GABA ratio values. On the whole, these apparent discrepancies emphasized the importance of a suitable biological characterization of the newly synthesized CBR ligands in order to appreciate their pharmacological profile.
In Vitro Efficacy in Excytotoxic-Mediate Injury. The disruptions in GABA signaling is involved in many acute and chronic neurodegenerative disorders such as temporal lobe epilepsy, Parkinson's disease (PD), Huntington's disease (HD), and brain ischemia. The GABAergic system is indeed indispensable to keep the balance between the excitation and the inhibition required for normal neuronal function. An imbalance between these systems contribute to excitotoxicity and neuronal cell death. Consequently, modulation of the GABAergic system can successfully reverse excitotoxic-induced injury in disease models, suggesting that therapeutic strategies targeting the GABAergic system could be effective in treating neurodegenerative disorders. 50−52 36 Cl − uptake measured in rat cerebrocortical synaptoneurosomes for compounds 10b (magenta), 10c (blue), 10d (cyan), flunitrazepam (empty circles), flumazenil (empty diamonds), and ethyl β-carboline (empty squares). Figure 8 . Effects of 7l,q,r, 8i, and diazepam on oxygen−glucose deprivation and reoxygenation (OGD/R)-induced release of LDH of rat brain cortical slices. Slices were incubated in artificial cerebrospinal fluid (ACSF) for 120 min (control conditions, CTRL) or subjected for 30 min to oxygen/glucose deprivation followed by 90 min incubation in normally oxygenated ACSF (reperfusion). Increasing concentrations of the compounds (0.1−100 μM) were added to ACSF during the 90 min reperfusion phase. Data are means ± SEM of at least four different experiments.°°°P < 0.01 vs CTRL; *P < 0.05, **P < 0.01, ***P < 0.001 vs OGD/R (ANOVA followed by Dunnet post-test).
Article activity. Rat cortical brain slices were subjected to excitotoxicmediated damage (i.e., oxygen-glucose deprivation and reoxygenation, OGD/R) and neuronal injury/neuroprotection was assessed by measuring the release of lactate dehydrogenase (LDH). All drug molecules were added during reperfusion and their effects were compared to those exerted by diazepam. The results demonstrated that diazepam exerted neuroprotective effects according to a "U-shaped", hormetic-like, concentration−response curve, with an efficacy window of 0.5−10 μM (Figure 8 ). In this range, the maximum recovery in LDH release was 55.9%, which was observed at both 1 and 5 μM concentrations ( Table 4 ).
The hormetic effect of diazepam was already observed 54 and might be explained by considering that elevated diazepam levels at the synaptic cleft might cause an excessive activation of GABA A receptors, which increases the overload of Cl − and causes GABA A desensitization, thus resulting in depolarization and neuron damages. 58, 59 In the same way, imidazo[1,5-a]quinoline derivatives 7l,q,r, and 8i showed neuroprotective properties. All the compounds, in fact, reduced OGD/Rinduced LDH release in a hormetic-like fashion although with different efficacy windows. In particular, 8i and 7r were the most interesting compounds ( Figure 8 ) because they exerted their effects in a wider concentration range than diazepam (i.e., 1−25 μM 8i or 1−50 μM 7r), but the maximum recovery in LDH release was lower (39.5% and 44.4%, respectively, at 5 μM, see Table 4 ). Also, 7l,q reverted the release of the endocellular enzyme caused by the ischemia-like conditions but the maximum effect was observed at 50 μM concentration and the recovery was 44%. Taken together, these results suggests that 7l,q,r and 8i could behave as partial agonists at GABA A receptors in the present experimental model because they exhibited lower efficacy than the positive GABA A modulator diazepam.
In Vivo Efficacy. The newly synthesized compounds 7a,c,d,l,m,p,q,r,w were evaluated in mice as modulators of central nervous system functionalities after per os administration. In particular, four pharmacological actions were taken into consideration. The light−dark box test was used to ascertain the potential anxiolytic effect, while the rota-rod test measured the myorelaxant effect, the hole-board test was performed to assess the effects on mouse spontaneous motility and explorative activity, and the passive avoidance test was finally used to evaluate the mouse learning and memory impairment.
The anxiolytic effect of the molecules is shown in Figure 9 . The light−dark box test is based on the innate aversion of rodents to the brightly lit and open areas and on the spontaneous novelty-induced exploratory behavior, allowing the evaluation of potential anxiolytic compounds. All compounds, with the exception of 7p, increased the time spent in the light box after dosing at 10 mg kg −1 . Compounds 7d (167.2 ± 6.5 s), 7r (172.5 ± 7.2 s), and 7w (181.4 ± 8.3 s) were the most effective showing a comparable effect with diazepam (1 mg kg −1 subcutaneously) ( Figure 9 ). Compound 7d presented a dose-dependent anxiolytic effect, which was significant starting from 3 mg kg −1 (144.8 ± 6.3 s; data not shown). A similar potency was showed by compound 7l, which was active starting from 3 mg kg −1 (153.4 ± 6.1 s; data not shown) peaking at 10 mg kg −1 ( Figure 9 ). Compound 7m was the most potent because it was effective at 1 mg kg −1 ( Figure  9 ), whereas 7p was ineffective when administered at 1 and 10 mg kg −1 ( Figure 9 ), but by increasing the dose to 30 mg kg
the time was enhanced up to 139.2 ± 5.1 s (data not shown).
To validate the behavioral measurements, possible neurological or muscular side effects of the tested compounds were excluded by the hole-board and the rota-rod tests. All the compounds (10 mg kg −1 ) did not alter the neurological and muscular abilities of the mice as evaluated by the hole-board test 30 min after treatment. The number of movements (motor activity) and the number of inspections (exploratory activity) were comparable to vehicle-treated animals ( Figure 10 ).
Similarly, no negative effects on motor coordination emerged in the rota-rod test ( Figure 11 ). The treated animals showed a progressive ability to maintain the balance on a rotating rod.
The nootropic effects were assessed in the passive avoidance test measuring the prevention of scopolamine-induced amnesia. The muscarinic antagonist drastically reduced the time spent in the light box of the apparatus during the retention session (44.8 ± 8.1 s vs 101.4 ± 7.0 s of vehicle-treated animals; second experimental day) highlighting a lack of memory of the punishment received in the dark box ( Figure 12 ). Compounds 7c,d,l,m,p,q,r,w (10 mg kg −1 ) were able to significantly prevent 55.9 ± 5.9*** a Rat cortical brain slices were subjected to oxygen-glucose deprivation and reoxygenation and neuronal injury/neuroprotection was assessed by measuring the release of lactate dehydrogenase (LDH). All drugs were added during reperfusion. b The efficacy windows represent the range of concentrations at which a significant reduction of OGD and reperfusion-induced LDH release was observed.
c EC (effective concentration) is the μM concentration at which the highest reduction was observed. The recovery value represents the % of reversion exerted at EC concentration; 100% was taken as the return to basal values (CTRL). Recovery data are reported as mean ± SEM and the comparison between values was performed by using ANOVA followed by Dunnet post-hoc test.*P < 0.05, ***P < 0.001 vs OGD/R. 
Article scopolamine-induced amnesia ( Figure 12 ). Compound 7w was the most effective (99.6 ± 9.2 s), and both 7r and 7w were effective also at 1 mg kg Thus, this promising evidence paves the way to the application of our approach to the study of the 5-HT 3 receptor to the characterization of the interaction of CBR with divalent and more in general multivalent ligands. 60 Fluoroderivative 7w (K i = 0.44 nM) resulted the most potent ligand and despite its inverse agonist−antagonist profile suggested by its GABA ratio value of 0.8, acted as an agonist in the light−dark box test, the classical animal model of anxiety, and was devoid of the undesired myorelaxant side effects. In addition, compound 7w (at 1 mg kg
) was found to significantly prevent scopolamineinduced amnesia, showing the best efficacy among the compounds evaluated in the in vivo studies (7a,c,d,l,m,p,q,r). Furthermore, imidazo[1,5-a]quinoline derivatives 7l,q,r, and 8i showed neuroprotective properties because they reduced LDH release induced by ischemia-like condition in an hormetic-like fashion although with different efficacy windows.
■ EXPERIMENTAL SECTION
Chemistry. All chemicals used were of reagent grade. Yields refer to purified products and are not optimized. Melting points were determined in open capillaries on a Gallenkamp apparatus and are uncorrected. Merck silica gel 60 (230−400 mesh) was used for column chromatography. Merck TLC plates, silica gel 60 F 254 were used for TLC. NMR spectra were recorded by means of either a Bruker AC 200 or a Bruker DRX 400 AVANCE spectrometers in the indicated solvents (TMS as internal standard); the values of the chemical shifts are expressed in ppm and the coupling constants (J) in Hz.
The purity of compounds 7a−aa, 8a−i, 9, and 10a−d was assessed by RP-HPLC and was found to be higher than 95%. An Agilent 1100 series system equipped with a Phenomenex C18 (3.9 mm × 150 mm, 10 μm) column or a Zorbax Eclipse XBD-C8 (4.6 mm × 150 mm, 5 μm) column was used in the HPLC analysis with acetonitrile− methanol−water (10:20:70) or (10:40:50) or (10:50:40) or (10:70:20) as the mobile phases at a flow rate of 2.0 mL/min. UV detection was achieved at 254 nm. Mass spectra were recorded on either a Thermo LCQ-Deca or an Agilent 1100 LC/MSD.
General Procedure for the Synthesis of Target Imidazo[1,5-a]quinoline Derivatives 7a−i,k−m,o−y. A mixture of the suitable 2-chloroquinoline derivative (11−24, 1 equiv) was cooled at 0−5°C in dry DMF (typically, 10 mL for 1 mmol) under argon and then treated with the suitable isocyanoacetate (3 equiv) and potassium tertbutoxide (3 equiv). The resulting mixture was stirred for 30 min at 0− 5°C, then allowed to stir at room temperature for 1 h, and finally heated at 80°C for 1−20 h (following the reaction progress by TLC). Passive avoidance test. Effects on learning and memory. All compounds were administered per os 30 min before the test. Scopolamine (1.5 mg kg −1 intraperitoneally) was administered immediately after the punishment. The time recorded during the retention session is reported. Each value represents the mean ± SEM of at least 10 mice. *P < 0.05 and **P < 0.01 in comparison to vehicletreated mice.
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Article After cooling to room temperature, acetic acid (typically, 1.0 mL for 1 mmol) was added and the mixture was stirred for additional 20 min and then poured onto crushed ice. The precipitate was collected by filtration, washed with water, dissolved into chloroform, and the organic layer washed with brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The residue was purified by flashchromatography with the suitable eluent to afford the expected imidazo[1,5-a]quinoline derivative (7a−i,k−m,o−y), which after recrystallization from the suitable solvent gave an analytical sample.
Ethyl 5-(Dimethylcarbamoyl)imidazo[1,5-a]quinoline-3-carboxylate (7a). The title compound was obtained as a white solid from 11 according to the above general procedure and purified by flash chromatography with ethyl acetate as the eluent (yield 35%). An analytical sample was obtained by recrystallization from ethyl acetate− chloroform by slow evaporation (white crystals, mp 209−210°C). 1 38 according to the above general procedure and purified by flash chromatography with ethyl acetate−n-hexane (8:2) as the eluent to obtain 7t as a white solid (yield 55%). An analytical sample was obtained by recrystallization from diethyl ether by slow evaporation (X-ray quality pale-yellow prisms, mp 142−143°C). 1 5 -a]-quinoline-3-carboxylate (7y). The title compound was prepared from 24 according to the above general procedure (except that the reaction was carried out at 0−5°C for 2 h and then at room temperature for 2 h) and purified by flash chromatography with ethyl acetate−petroleum ether (7:3) as the eluent to obtain 7y as a white solid (yield 62%, mp 177−178°C). Because the amide nitrogen of the compound bears two different substituents, its 1 H NMR spectrum (CDCl 3 ) shows the presence of a (ca. 6:4) mixture of two rotamers in equilibrium; for the sake of simplification, the integral values have not been reported. were added. The reaction mixture was allowed to stir at room temperature for 30 min, then refluxed for 20 h, and finally filtered and concentrated under reduced pressure. The residue was dissolved into dichloromethane, and the organic layer was washed with a saturated solution of sodium bicarbonate, dried over sodium sulfate, and concentrated under reduced pressure. Purification of the residue by flash chromatography with ethyl acetate−n-hexane (7:3) as the eluent gave 7aa as an oil which slowly crystallized on standing (12 mg, yield 46%). Because the amide nitrogen of this compound bears two different substituents, its 1 H NMR spectrum shows the presence of a (ca. 6:4) mixture of two different rotamers in equilibrium; for the sake of simplification, the integral values have not been given. 1 
Article N-Benzyl-N-methyl-5-phenylimidazo[1,5-a]quinoline-3-carboxamide (8d). This compound was prepared by using the same procedure described for 8c (except that N-methylbenzylamine was used instead of dimethylamine) and purified by flash chromatography with nhexane−ethyl acetate (1:1) as the eluent to obtain 8d as a white solid (yield 48%, mp 157−159°C . This compound was prepared from acid 33 by using the same procedure described for 8c (except that N-methylbenzylamine was used instead of dimethylamine) and purified by flash chromatography with ethyl acetate as the eluent to obtain 8f as a paleyellow glassy solid (yield 67%). Because the amide nitrogen of this compound bears two different substituents, its General Procedure for the Synthesis of Target Imidazo[1,5-a]quinoxaline Derivatives 10a−d. A solution of the suitable 4-acetyl-3,4-dihydroquinoxalin-2(1H)-one derivative (38 or 39) in dry THF was cooled at 0°C for 10 min under argon and then treated with potassium tert-butoxide. The resulting mixture was allowed to warm at room temperature and stirred for 45 min under argon atmosphere. Then, it was cooled to −55°C, diethyl chlorophosphate was added, and the resulting mixture was stirred at −55°C for 15 min and finally at room temperature for 45 min. The reaction mixture was cooled again at −55°C and then treated with the suitable isocyanoacetate and potassium tert-butoxide. The resulting mixture was allowed to stir at −55°C for 2 h and finally at room temperature for 30 min. Then, glacial acetic acid was added and the reaction mixture was concentrated under reduced pressure. The residue was dissolved into CHCl 3 and washed with water and with brine. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. Purification of the residue by flash chromatography with the appropriate eluent gave the expected target derivative (10a−d).
Ethyl 5-Acetyl-4,5-dihydroimidazo[1,5-a]quinoxaline-3-carboxylate (10a). This compound was prepared from 38 31 (2.0 g, 10.5 mmol), potassium tert-butoxide (1.3 g, 11.6 mmol), diethyl chlorophosphate (1.68 mL, 11.6 mmol), ethyl isocyanoacetate (1.8 mL, 16.5 mmol), and potassium tert-butoxide (1.3 g, 11.6 mmol) according to the above general procedure and purified by flash chromatography with ethyl acetate as the eluent to obtain 10a as an off-white crystalline solid (1.22 g, yield 41% ). An analytical sample was obtained by recrystallization from ethyl acetate (colorless prisms, mp 173−174°C). 1 tert-Butyl 2-Chloro-3-methylquinoline-4-carboxylate (16) . A solution of acid chloride 25 38 (3.5 g, 14.6 mmol) in dry THF (15 mL) was cooled at 0−5°C, and a mixture of potassium tert-butoxide (1.64 g, 14.6 mmol) in 15 mL of dry THF was added. The resulting mixture was stirred at the same temperature for 10 min and at room temperature for 30 min. The reaction mixture was then poured onto crushed ice, and the precipitate was collected by filtration, dried under reduced pressure, and purified by flash chromatography with petroleum ether−ethyl acetate (9:1) as the eluent to obtain 16 as a white solid (3.4 g, yield 84% ). An analytical sample was obtained by recrystallization from n-hexane (mp 107−108°C). (22) . A mixture of acid 27a (1.0 g, 4.43 mmol) in thionyl chloride (5.0 mL) was refluxed under argon for 2 h. The thionyl chloride excess was then removed under reduced pressure, and the resulting acid chloride was immediately used without further purification. To a mixture of acid chloride in 20 mL of dichloromethane cooled at 0−5°C, dipropylamine (0.57 mL, 4.16 mmol) and triethylamine (TEA, 1.0 mL) were added and the resulting mixture was stirred at room temperature for 30 min while the reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure and partitioned between CH 2 Cl 2 and water. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by flash chromatography with nhexane−ethyl acetate (8:2) as the eluent to obtain 22 as pale-yellow oil, which slowly crystallized on standing (1.1 g, yield 86%). 1 (23) . A mixture of acid 27a (1.0 g, 4.43 mmol) in thionyl chloride (5.0 mL) was refluxed under argon for 2 h. The thionyl chloride excess was then removed under reduced pressure, and the resulting acid chloride was immediately used without further purification. To a mixture of acid chloride in 20 mL of dichloromethane cooled at 0−5°C, Nmethylbenzylamine (0.53 mL, 4.11 mmol) and TEA (1.0 mL) were added and the resulting mixture was stirred at room temperature for 30 min while the reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure and partitioned between CH 2 Cl 2 and water. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by flash chromatography with n-hexane− ethyl acetate (7:3) as the eluent to obtain 23 as pale-yellow oil, which slowly crystallized on standing (1.1 g, yield 81%, mp 97−98°C). Because the amide nitrogen of this compound bears two different substituents, its 1 H NMR spectrum shows the presence of two different rotamers in equilibrium; for the sake of simplification, the integral intensities have not been given. 1 N-Benzyl-6-bromo-2-chloro-N-methylquinoline-4-carboxamide (24) . A mixture of acid 27b (1.3 g, 4.54 mmol) in dichloromethane (20 mL) and thionyl chloride (5.0 mL) was refluxed under argon for 3 h. The volatile was then removed under reduced pressure, and the resulting acid chloride was immediately used without further purification. To a mixture of acid chloride in 20 mL of dichloromethane cooled at 0−5°C, N-methylbenzylamine (1.2 mL, 9.3 mmol) and TEA (1.0 mL) were added, and the resulting mixture was stirred at room temperature for 30 min while the reaction progress was monitored by TLC. The reaction mixture was washed with water, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by flash chromatography with nhexane−ethyl acetate (7:3) as the eluent to obtain 24 as a white solid (1.0 g, yield 57%, mp 127−128°C). Because the amide nitrogen of this compound bears two different substituents, its . A mixture of 6-fluoro-2-hydroxy-4-quinolinecarboxylic acid (26a, 41 3.0 g, 14.5 mmol) in 15 mL of POCl 3 was heated to reflux for 2 h and then poured onto crushed ice. The precipitate was extracted with chloroform, and the organic layer was dried over sodium sulfate and concentrated under reduced pressure. Purification of the residue by washing with n-hexane gave acid 27a (2.3 g, yield 70%), which was promptly used in the subsequent step. 6-Bromo-2-chloro-4-quinolinecarboxylic Acid (27b). A mixture of 6-bromo-2-hydroxy-4-quinolinecarboxylic acid (26b) (1.0 g, 3.7 mmol) in 10 mL of POCl 3 was heated to reflux for 3 h and then poured onto crushed ice. The precipitate was extracted with ethyl acetate, and the organic layer was dried over sodium sulfated and concentrated under reduced pressure. Purification of the residue by washing with n-hexane gave acid 27b (1.0 g, yield 94%), which was promptly used in the subsequent step. (33) . A mixture of 8e (0.20 g, 0.558 mmol) in formic acid (10 mL) was stirred at room temperature overnight and then concentrated under reduced pressure to obtain acid 33 (0.15 g, yield 89%), which was used in the subsequent step without further purification.
2-Chloro-3-hydroxymethyl-4-phenylquinoline (34) . To a 1 M solution of lithium aluminum hydride (LAH, 20 mL, 20 mmol) cooled at 0−5°C, a solution of 30 62 (3.0 g, 9.62 mmol) in THF (40 mL) was added and the resulting mixture was stirred at the same temperature for 15 min. The LAH excess was then decomposed with water, and the reaction mixture was filtered and concentrated under reduced pressure. The residue was partitioned between dichloromethane and water, and the organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. Purification of the residue by flash chromatography with n-hexane−ethyl acetate (1:1) as the eluent afforded 34 (1.21 g, yield 47%), which was used in the subsequent step without further purification. The resulting mixture was stirred at the same temperature for 15 min and then at room temperature for 2.5 h. The reaction mixture was partitioned between dichloromethane and water, and the organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to afford 35 (1.4 g, yield 82%), which was used in the subsequent step without further purification. X-ray Crystallography. Single crystals of compounds 7p,s,t and 10a−c were submitted to X-ray data collection on an OxfordDiffraction Xcalibur Sapphire 3 diffractometer with a graphite monochromated Mo Kα radiation (λ = 0.71073 Å) at 293 K. The structures were solved by direct methods implemented in SHELXS-97 program. 63 The refinements were carried out by full-matrix anisotropic least-squares on F 2 for all reflections for non-H atoms by means of the SHELXL-97 program. 64 Crystallographic data (excluding structure factors) concerning the structures solved in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1437490 (7p), 1437488 (7s), 1437489 (7t), 1437487 (10a), 1437486 (10b), and 1446645 (10c). Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; (fax: + 44 (0) 1223 336 033; or e-mail: deposit@ccdc.cam.ac.uk).
Radioligand Binding Studies in Native Bovine and Human Cerebral Receptors. [ 3 H]Flumazenil (specific activity 70.8 Ci/ mmol) was obtained from PerkinElmer Life Science (Milano, Italy). All other chemicals were at reagent grade and were obtained from commercial suppliers.
Bovine cortex was obtained from the local slaughterhouse. Human cortex samples were taken post-mortem at the Department of Pathological Anatomy, University of Pisa, during autopsy sessions. The subjects had died from causes not primarily involving the brain and had not suffered from any psychiatric or neurological disorders.
The time between death and tissue dissection/freezing ranged from 18 to 36 h. The samples were immediately packed in dry ice and stored in a −80°freezer. The study was approved by the Ethics Committee of the University of Pisa, Italy.
Bovine and human cerebral cortex membranes were prepared in agreement with Martini et al. 65 Briefly, cerebral cortex was homogenized in 10 volumes of ice cold 0.32 M sucrose containing protease inhibitors. The homogenate was centrifuged at 1000g for 10 min at 4°C, the resulting pellet was discarded, and the supernatant was recentrifuged at 48000g for 15 min at 4°C. Then the pellet was osmotically shocked by suspension in 10 volumes of 50 mM Triscitrate buffer at pH 7.4 containing protease inhibitors and recentrifuged at 48000g for 15 min at 4°C. The resulting membranes were frozen and washed by means of the procedure previously described for removing endogenous GABA from cerebral cortex. 66 Finally, the pellet was suspended in 10 volumes of 50 mM Tris-citrate buffer pH 7.4 and used in the binding assay. Protein concentration was assayed by the method of Lowry et al. 67 by means of bovine serum albumin as the standard.
[ In Vitro Efficacy in 36 Cl − Uptake Assay in Rat Cerebrocortical Synaptoneurosomes.
36 Cl − (specific activity 9.69 μCi/g) was obtained from PerkinElmer Life Science (Milan, Italy). All other chemicals were reagent grade and were obtained from commercial suppliers.
The 36 Cl − uptake was measured in rat cerebrocortical synaptoneurosomes as described by Schwartz et al., 48 with minor modifications. Briefly, the cerebral cortex was dissected from Sprague−Dawley male rats suspended 1:10 with ice-cold solution containing 145 mM NaCl, 5 mM KCl, 5 mM MgCl 2, 1 mM CaCl 2 , 10 mM HEPES, pH 7 (T1 buffer), and 10 mM D-glucose; they were homogenized with a glass− glass homogenizer (five strokes) and filtered through three layers of nylon mesh (160 μm) and a 10 μm Millipore filter. The filtrates were centrifuged at 1000g for 15 min. After discarding the supernatant, the pellet was gently resuspended in T1 buffer and washed once more by centrifugation (1000g for 15 min). The final pellet containing the synaptoneurosomes was suspended 1:2 in T1 buffer and kept on ice until ready for assay (no longer than 30 min).
Aliquots of synaptoneurosome suspensions (1.5−2 mg of protein) were preincubated at 30°C for 10 min prior to the addition of 0. 
Cl
− uptake was stopped 10 s later by the addition of 5 mL of ice-cold HEPES, followed by vacuum filtration through glass fiber filters (Whatman GF/B) that had been soaked with 0.05% polyethylenimine to reduce nonspecific binding of 36 Cl
−
. The filters were washed three more times with 5 mL of ice-cold buffer and
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Article placed into scintillation vials containing 4 mL of Ready Protein Beckman scintillation cocktail, and radioactivity was counted in a Packard LS 1600 liquid-phase scintillation β counter. Data are expressed as percent stimulation of 36 Cl − uptake above basal level. In Vitro Efficacy in Excitotoxic-Mediated Injury. Compounds. Trizma base, ascorbic acid, sodium pyruvate, sodium EGTA, β-nicotinamide adenine dinucleotide (NAD+), β-nicotinamide adenine dinucleotide reduced form (NADH), and all artificial cerebrospinal fluid (ACSF) components were purchased from Sigma-Aldrich Co. (St Louis, MO, U.S.A.). Drugs molecules were solubilized into DMSO and diluted at the final desired concentration with ACSF immediately before the experiment. Final DMSO concentration in the ACSF used for the experiments was always lower than 0.1%, and this had no effect per se on the biochemical parameters investigated. 54, 59 All other materials were from standard local commercial sources and of the highest grade available.
Animals. All animal care and experimental protocols were in strict compliance with the European Union Guidelines for the Care and the Use of Laboratory Animals (the European Union Directive 2010/63/ EU) and were approved by the Italian Department of Health (813/ 2015-PR).
Sprague−Dawley male rats (300−350 g; Charles River Italia, Calco, Italy) were kept in large cages under a 12:12 h day−night cycle at 20°C ambient temperature. Drinking water and conventional laboratory rat food were available ad libitum. Before sacrifice, animals were anaesthetized by intraperitoneal injection of a mixture of Ketavet (30 mg/kg ketamine; Gellini, Aprilia, Italy) and xylazine (8 mg/kg Xilor; Bayer AG, Wuppertal, Germany).
Preparation of Slices. After the sacrifice of the animal (by decapitation) the whole brain was rapidly removed, chilled to 4°C by immersion into cold ACSF (composition in mM: 120 NaCl, 2.5 KCl, 1.3 MgCl 2 , 1.0 NaH 2 PO 4 , 1.5 CaCl 2 , 26 NaHCO 3 , 11 glucose, saturated with 95% O 2 −5% CO 2 , with a final pH of 7.4, osmolality 285−290 mOsmol). The cortex was dissected and cut into 400 μm thick slices by using a manual chopper (Stoelting Co., Wood Dale, IL, USA). Afterward, slices were maintained in oxygenated ACSF enriched with 400 μM ascorbic acid for 1 h at room temperature to allow maximal recovery from slicing trauma. 59 In Vitro Ischemia-Like Conditions. Cortical slices from a single brain were placed in covered incubation flasks containing ACSF (2 mL) continuously bubbled with a 95% O 2 −5% CO 2 gas mixture and incubated at 37°C for an additional period of 30 min. Afterward, OGD was carried out by incubating slices for 30 min into ACSF in which glucose was replaced by an equimolar amount of sucrose and continuously bubbled with a 95% N 2 −5% CO 2 gas mixture. After the OGD phase, the ischemic-like solution was replaced by fresh, oxygenated ACSF for an additional 90 min period (reoxygenation phase). The protective effect of the tested compounds was investigated by adding them to ACSF during the entire reoxygenation phase.
Assessment of Tissue Injury. Cell damage was assessed by measuring the amount of LDH released into the ACSF during the entire reperfusion period. 54, 59 LDH activity was determined spectrophotometrically via the rate of decrease in absorbance at 340 nm of NADH during its oxidation to NAD + and the concomitant reduction of pyruvate to lactate.
Data Analysis. Each experimental block was performed by using brain slices derived from at least four rats. The data are reported as mean ± SEM, and statistical analysis was performed by using one-way ANOVA followed by Dunnet post-test (GraphPad Software, San Diego, CA, USA). In all comparisons, the level of statistical significance (P) was set at 0.05.
In Vivo Efficacy. The experiments were carried out in accordance with the Animal Protection Law of the Republic of Italy, DL No. 116/ 1992, based on the European Communities Council Directive of November 24, 1986 (86/609/EEC). All efforts were made to minimize animal suffering and to reduce the number of animals involved. Male CD-1 albino mice (22−24 g ) and male Swiss Webster (20−26 g) (Morini, Italy) were used. Twelve mice were housed per cage and fed a standard laboratory diet, with tap water ad libitum for 12 h/12 h light−dark cycles (lights on at 7:00). The cages were brought into the experimental room the day before the experiment for acclimatization purposes. All experiments were performed between 10:00 and 15:00.
Rota-rod Test. The integrity of the animals' motor coordination was assessed using a Rota-rod apparatus (Ugo Basile, Varese, Italy) at a rotating speed of 16 rpm. The treatment was performed before the test. The numbers of falls from the rod were counted for 30 s, 30 min after drug administration, and the test was performed according to the method described by Vaught et al. 70 Light−Dark Box Test. The apparatus (50 cm long, 20 cm wide, and 20 cm high) consisted of two equal acrylic compartments, one dark and one light, illuminated by a 60 W bulb lamp and separated by a divider with a 10 cm × 3 cm opening at floor level. Each mouse was tested by placing it in the center of the lighted area, away from the dark one, and allowing it to explore the novel environment for 5 min. The number of transfers from one compartment to the other and the time spent in the illuminated side were measured. This test exploited the conflict between the animal's tendency to explore a new environment and its fear of bright light. 71 Passive-Avoidance Test. The test was performed according to the step-through method described by Jarvik et al. 72 The apparatus consisted of a two-compartment acrylic box with a lighted compartment connected to a darkened one by a guillotine door. As soon as the mouse entered the dark compartment, it received a thermal shock punishment. The latency times for entering the dark compartment were measured in the training test and after 24 h in the retention test. The maximum entry latency allowed in the training and retention sessions was, respectively, 60 and 180 s.
Hole-Board Test. The hole-board test consisted of a 40 cm 2 plane with 16 flush-mounted cylindrical holes (3 cm diameter) distributed four by four in an equidistant, grid-like manner. Mice were placed on the center of the board one by one and allowed to move about freely for a period of 5 min each. Two electric eyes, crossing the plane from midpoint to midpoint of the opposite sides, thus dividing the plane into four equal quadrants, automatically signaled the movement of the animal (counts in 5 min) on the surface of the plane (spontaneous motility). Miniature photoelectric cells in each of the 16 holes recorded (counts in 5 min) the exploration of the holes (exploratory activity) by the mice. A total of 12−15 mice per group were tested. 73 Compound Administration. Diazepam (Valium 10, Roche) was dissolved into isotonic (NaCl 0.9%) saline solution and injected subcutaneously. The new compounds were administered by the po route and were suspended in 1% carboxymethylcellulose sodium salt and sonicated immediately before use. Drug concentrations were prepared in such a way that the necessary dose could be administered in a 10 mL/kg volume of carboxymethylcellulose 1% by the per os or subcutaneous route.
Statistical Analysis. All experimental result are given as the mean ± SEM. Each value represents the mean of 25 mice. An analysis of variance, ANOVA, followed by Fisher's protected least significant difference procedure for post hoc comparison, were used to verify significance between two means of behavioral results. The data were analyzed with the StatView software for Macintosh (1992) . P values of less than 0.05 were considered significant.
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